Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.
“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement....
Secretome Therapeutics, a Dallas-based biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells, has appointed Margot Connor to its board of directors and announced the appointment of its clinical advisory board composed of world-class clinicians and researchers in the field of heart failure.
“I have been fortunate to be part of the stem cell-based therapy evolution, and I believe secretomes are a true breakthrough in this extraordinary field,” Connor said in a statement....